PMID- 32844570 OWN - NLM STAT- MEDLINE DCOM- 20210812 LR - 20210812 IS - 1759-7714 (Electronic) IS - 1759-7706 (Print) IS - 1759-7706 (Linking) VI - 11 IP - 10 DP - 2020 Oct TI - Efficacy and safety of S-1 monotherapy in previously treated elderly patients (aged >/=75 years) with non-small cell lung cancer: A retrospective analysis. PG - 2867-2876 LID - 10.1111/1759-7714.13622 [doi] AB - BACKGROUND: S-1 monotherapy is effective and feasible for previously treated patients with advanced non-small cell lung cancer (NSCLC). However, it is not clear whether its effectiveness and tolerability in elderly patients are equivalent to those in younger patients. Hence, this study aimed to evaluate the efficacy and feasibility of S-1 monotherapy in elderly patients with NSCLC who had previously received other treatments. METHODS: We included 96 elderly patients (aged >/=75 years) with advanced NSCLC treated with S-1 alone as a subsequent-line treatment at 12 medical facilities between January 2005 and March 2018 in this study. The baseline characteristics of the patients, response to S-1 monotherapy, and adverse events (AEs) were investigated, retrospectively. RESULTS: A total of 68 male and 28 female patients (median age, 78 [range: 75-86] years) were analyzed. In elderly patients who were treated with S-1 monotherapy as a subsequent-line treatment, the objective response rate, disease control rate, median progression-free survival (PFS), and overall survival (OS) were 8.3%, 43.8%, 3.4 months, and 9.6 months, respectively. Observed AEs included anorexia, anemia, nausea, fatigue, reduced platelet count, and skin hyperpigmentation. Treatment-related death was observed in one patient because of pneumonitis. In patients who experienced no progressive disease, subsequent-line S-1 alone was associated with longer PFS and OS. CONCLUSIONS: S-1 monotherapy is effective and feasible as a subsequent-line treatment in elderly patients who were previously treated for NSCLC, and it produces results. S-1 monotherapy could be one of the treatment choices for elderly patients with previously treated NSCLC. CI - (c) 2020 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd. FAU - Imai, Hisao AU - Imai H AUID- ORCID: 0000-0003-3097-4255 AD - Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan. AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan. FAU - Minemura, Hiroyuki AU - Minemura H AUID- ORCID: 0000-0001-8710-1960 AD - Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan. FAU - Kishikawa, Takayuki AU - Kishikawa T AUID- ORCID: 0000-0002-8957-4814 AD - Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan. FAU - Yamada, Yutaka AU - Yamada Y AD - Division of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan. FAU - Suzuki, Kensuke AU - Suzuki K AD - Division of Internal Medicine, Toyama Prefectural Central Hospital, Toyama, Japan. FAU - Umeda, Yukihiro AU - Umeda Y AD - Third Department of Internal Medicine, Faculty of Medical Sciences, University of Fukui, Eiheiji, Japan. FAU - Wasamoto, Satoshi AU - Wasamoto S AD - Division of Respiratory Medicine, Saku Central Hospital Advanced Care Center, Saku, Japan. FAU - Kasahara, Norimitsu AU - Kasahara N AUID- ORCID: 0000-0001-6971-7411 AD - Innovative medical research center, Gunma University Hospital, Maebashi, Japan. FAU - Ishihara, Shinichi AU - Ishihara S AD - Department of Internal Medicine, Isesaki Municipal Hospital, Isesaki, Japan. FAU - Yamaguchi, Ou AU - Yamaguchi O AUID- ORCID: 0000-0001-7194-6459 AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan. FAU - Naruse, Ichiro AU - Naruse I AD - Division of Respiratory Medicine, Hidaka Hospital, Takasaki, Japan. FAU - Uchino, Junji AU - Uchino J AD - Department of Pulmonary Medicine, Kyoto Prefectural University of Medicine, Kyoto, Japan. FAU - Mori, Keita AU - Mori K AD - Clinical Research Promotion Unit, Clinical Research Center, Shizuoka Cancer Center, Nagaizumi, Japan. FAU - Kanazawa, Kenya AU - Kanazawa K AD - Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan. FAU - Shibata, Yoko AU - Shibata Y AD - Department of Pulmonary Medicine, Fukushima Medical University, Fukushima, Japan. FAU - Kasai, Takashi AU - Kasai T AD - Division of Thoracic Oncology, Tochigi Cancer Center, Utsunomiya, Japan. FAU - Kaburagi, Takayuki AU - Kaburagi T AD - Division of Respiratory Medicine, Ibaraki Prefectural Central Hospital, Kasama, Japan. FAU - Kaira, Kyoichi AU - Kaira K AUID- ORCID: 0000-0001-5548-7686 AD - Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Hidaka, Japan. FAU - Minato, Koichi AU - Minato K AD - Division of Respiratory Medicine, Gunma Prefectural Cancer Center, Ota, Japan. LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20200826 PL - Singapore TA - Thorac Cancer JT - Thoracic cancer JID - 101531441 RN - 0 (Drug Combinations) RN - 150863-82-4 (S 1 (combination)) RN - 1548R74NSZ (Tegafur) RN - 5VT6420TIG (Oxonic Acid) SB - IM MH - Aged MH - Aged, 80 and over MH - Carcinoma, Non-Small-Cell Lung/*drug therapy/pathology MH - Drug Combinations MH - Female MH - Humans MH - Lung Neoplasms/*drug therapy/pathology MH - Male MH - Oxonic Acid/pharmacology/*therapeutic use MH - Retrospective Studies MH - Tegafur/pharmacology/*therapeutic use PMC - PMC7529563 OTO - NOTNLM OT - Advanced non-small cell lung cancer OT - S-1 monotherapy OT - elderly patients OT - subsequent-line therapy EDAT- 2020/08/28 06:00 MHDA- 2021/08/13 06:00 PMCR- 2020/10/01 CRDT- 2020/08/27 06:00 PHST- 2020/06/04 00:00 [received] PHST- 2020/07/28 00:00 [revised] PHST- 2020/07/30 00:00 [accepted] PHST- 2020/08/28 06:00 [pubmed] PHST- 2021/08/13 06:00 [medline] PHST- 2020/08/27 06:00 [entrez] PHST- 2020/10/01 00:00 [pmc-release] AID - TCA13622 [pii] AID - 10.1111/1759-7714.13622 [doi] PST - ppublish SO - Thorac Cancer. 2020 Oct;11(10):2867-2876. doi: 10.1111/1759-7714.13622. Epub 2020 Aug 26.